Amos Kirilovsky

Délégation Paris 5 — France

Medicine · Health Sciences

27h-index28.9kcitations85works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(64), Colorectal Cancer Surgical Treatments(32), Colorectal Cancer Treatments and Studies(25), Colorectal and Anal Carcinomas(22), Inflammatory mediators and NSAID effects(12)

Publications85 total

Reply to Z. Gao et al
Journal of Clinical Oncology·2024
International Validation of the Immunoscore Biopsy in Patients With Rectal Cancer Managed by a Watch-and-Wait Strategy
Journal of Clinical Oncology·2023· 39 citedOpen Access
Multi-Institutional Evaluation of Pathologists’ Assessment Compared to Immunoscore
Cancers·2023· 10 citedOpen Access
Data from Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer
2023Open Access
Supplementary Figure 2 from Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer
2023Open Access
Data from A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy
2023Open Access
Supplementary Figure 1 from Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer
2023Open Access
Supplementary Tables 1 - 5 from Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer
2023Open Access
Supplementary Figure 2 from Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer
2023Open Access
Supplementary Tables 1 - 5 from Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer
2023Open Access
Supplementary Figures from A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy
2023Open Access
Supplementary Tables from A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy
2023Open Access
Supplementary Figure 1 from Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer
2023Open Access
Data from Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer
2023Open Access
Data from A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy
2023Open Access
Supplementary Figures from A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy
2023Open Access
Supplementary Tables from A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy
2023Open Access
Supplementary Figure 1 from Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer
2023Open Access
Supplementary Figure 2 from Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer
2023Open Access
Supplementary Tables 1 - 5 from Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Franck Pagès(44), Jérôme Galon(38), Florence Marliot(23), Carine El Sissy(23), Bernhard Mlecnik(22), Anne Berger(21), Gabriela Bindea(19), Wolf H. Fridman(15), Marie Tosolini(13), Patrick Bruneval(12), Tessa Fredriksen(12), Marc Van den Eynde(12), Nacilla Haicheur(12), Christine Lagorce(11), Zlatko Trajanoski(10), Ana-Maria Mușină(9), Guy Zeitoun(9), Viorel Scripcariu(9), Lucie Lafontaine(8), Christine Lagorce-Pagès(7)